Search
NP-50301
go.drugbank.com/drugs/DB05662ExperimentalIt is estimated that about 30% of postmenopausal women suffer symptoms of DES, which accounts for over 12 million women in the U.S. … NP-50301 is an ophthalmic therapeutic eye drop treating post-menopausal Dry Eye Syndrome (DES). It is being developed by Nascent Pharmaceuticals.
Rimacalib
go.drugbank.com/drugs/DB12571InvestigationalRimacalib has been used in trials studying the treatment of Rheumatoid Arthritis (RA).
Radotinib
go.drugbank.com/drugs/DB12323InvestigationalRadotinib is under investigation for the treatment of Leukemia, Myelogenous, Chronic, BCR-ABL Positive.
Cefovecin
go.drugbank.com/drugs/DB11505ExperimentalVet approvedCefovecin is a cephalosporin antibiotic used for the treatment of skin infections in cats and dogs. … It is used for the treatment of skin infections caused by Pasturella multocida in cats, and Staphylococcus intermedius/S. canis in dogs.
RS-39604
go.drugbank.com/drugs/DB17050ExperimentalRS-39604 is a selective 5-HT4 receptor antagonist.[A253112]
Salts: RS-39604 hydrochlorideSynonyms: Methanesulfonamide, n-(2-(4-(3-(4-amino-5-chloro-2-((3,5-dimethoxyphenyl)methoxy)phenyl)-3-oxopropyl)-1-piperidinyl)ethyl)-Glycogen Storage Disease Type Ia
go.drugbank.com/conditions/DBCOND0063604Drugs: Pariglasgene brecaparvovecSynonyms: Hepatorenal form of glycogen storage diseaseSLx-4090
go.drugbank.com/drugs/DB05678InvestigationalSLx-4090 is a microsomal triglyceride transfer protein (MTTP) inhibitor potentially for the treatment of type 2 diabetes. [A33218]
Ramoplanin
go.drugbank.com/drugs/DB04952ExperimentalRamoplanin is a novel glycolipodepsipeptide antibiotic under development for the treatment of CDAD.
AZD2389
go.drugbank.com/drugs/DB22104InvestigationalAZD2389 is an investigational small molecule inhibitor of fibroblast activation protein (FAP).[L54978] It is currently undergoing safety, tolerability, and PK/PD profiling in clinical trials (e.g. … NCT06973005: A Study to Investigate How Multiple Oral Doses of AZD2389 Affect the Pharmacokinetics of Midazolam, Caffeine, and Bupropion in Healthy Participants).
BOS172722
go.drugbank.com/drugs/DB15498InvestigationalThe key role of Mps1 in the growth of cancer cells renders it an appealing target for cancer treatment, as its inhibition could lead to favorable effects. … [A187120] An in vivo study combined BOS172722 with [Paclitaxel] for the treatment of triple hormone receptor negative breast cancer, and demonstrated promising synergistic effects.[A187123]